ReviewJournal of translational medicine2014
Role of estrogen in hepatocellular carcinoma: is inflammation the key?
Review in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Molecular mechanisms of sex hormones in Hepatocellular Carcinoma: a systematic review.Molecular biology reports · 2025Pooled it
- Tamoxifen for adults with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2024Pooled it
- Gene therapy for people with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2024Pooled it
- Menopausal hormone therapy and risk of liver cancer in a Swedish population-based cohort study.Journal of the National Cancer Institute · 2026Article
- Cell line-dependent effects of β‑estradiol and testosterone on aurora kinases, GATA3, and associated miRNAs in hepatocellular carcinoma models HepG2 and Huh‑7.Cancer cell international · 2026Article
- Scutellarin mediates cell cycle arrest and apoptosis in liver cancer through a novel circSRBD1/miR-2682-5p/ESR1 ceRNA axis.Journal of translational medicine · 2026Article
- Article
- The Impact of Cirrhosis Severity and Spironolactone on Sex Hormone Levels in Men.Gastro hep advances · 2026Article
- The importance of sex dimorphism in liver metabolism and progressive liver diseases.Biology of sex differences · 2025Review
- Sex and gender disparities in hepatocellular carcinoma: insights into risk, diagnosis, and therapeutic outcomes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Comprehensive phosphoproteomic profiling reveals sex-specific regulatory mechanisms in HrasG12V-driven hepatocarcinogenesis.Cancer cell international · 2025Article
- Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025Review
- Exploring the Mechanism of Luteolin in Protecting Chickens from Ammonia Poisoning Based on Proteomic Technology.Metabolites · 2025Article
- Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells.Journal of translational medicine · 2024Article
- Supportive care of female hormones in brain health: what and how?Frontiers in pharmacology · 2024Review
- An overview of risk assessment and monitoring of malignant transformation in cirrhotic nodules.Therapeutic advances in gastroenterology · 2024Review
- Loss of STAT3 in osteoblasts has detrimental and sexually dimorphic effects on skeletal development.PloS one · 2024Article
- The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer.Cells · 2023Review
- Review
- Long working hours and increased risks of lean non-alcoholic fatty liver disease among Korean men and women.Scientific reports · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and accounts for the third-leading cause of cancer-related deaths. Over the past decades, advances have been made in the field of surgery, but effective treatment of HCC is lacking. Due to a marked male predominance in morbidity and mortality in HCC patients, it has long been considered that sex hormones play a role in HCC development. Recently estrogen has been proven to exert protective effects against HCC through IL-6 restrictions, STAT3 inactivation and tumour-associated macrophage inhibition. While IL-6-dependent STAT3 activation is considered a key event in inflammation-induced liver cancer, the anti-inflammation effect of estrogen is well documented. The roles of the estrogen receptor and aromatase and interactions between microRNAs and estrogen in HCC have been investigated. In this review, we present a novel model to elucidate the mechanism of estrogen-mediated inhibition of HCC development through an anti-inflammation effect and provide new insights into the roles of estrogen in liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.